Last updated: February 27, 2026
What is NDC 51672-2075?
NDC 51672-2075 refers to a specific drug listed in the National Drug Code directory. Based on available data, this code corresponds to Humira (adalimumab) - auto-injector pen. Humira is a monoclonal antibody used to treat autoimmune diseases including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis.
Market Overview
Market Size and Key Drivers
Humira remains the top-selling biologic globally, with estimated global sales exceeding $21 billion in 2022. It accounts for a significant portion of the biologic segment[1]. The primary drivers include:
- Expanding indications, including ulcerative colitis, hidradenitis suppurativa, and Crohn’s disease.
- Increasing prevalence of autoimmune conditions globally.
- Off-label uses and combination therapy applications.
- Patent protection was historically a barrier, but now generic and biosimilar competition is emerging.
Competitive Landscape
The biologic space for rheumatoid arthritis and related conditions faces competition from:
- Embrel (etanercept)
- Stelara (ustekinumab)
- Cosentyx (secukinumab)
However, Humira's broad indication portfolio ensures continued market dominance until biosimilar entry.
Biosimilar Impact
Biosimilars launched in the U.S. since 2023. Amgen's Amjevita and Sandoz's Hyrimoz entered the market at a 15%-20% price discount. These biosimilars are expected to erode Humira’s market share over the next five years.
Pricing Trends and Projections
Current Pricing
- List price for a single Humira auto-injector pen (NDC 51672-2075) stands at approximately $2,500 per pen, according to manufacturer data and pharmacy estimates.
- Actual payer prices (net prices post discounts) are lower, settling around $1,200 - $1,500 per pen in hospital and specialty pharmacies.
Market Price Trends
- Pre-Pricing: Historically, Humira's list price increased approximately 7%-8% annually from 2015 to 2021.
- Post-Biosimilar Entry: Price erosion expected to reach 20%-30% over the next 2-3 years as biosimilars gain adoption[2].
Future Price Projections
| Year |
Predicted List Price per Pen |
Expected Net Price (after discounts) |
Key Factors |
| 2023 |
$2,500 |
$1,200 |
Biosimilar competition begins |
| 2024 |
$2,250 |
$1,050 |
Increased biosimilar uptake |
| 2025 |
$2,000 |
$900 |
Market penetration stabilizes |
| 2026 |
$1,750 |
$800 |
Further biosimilar competition |
Market Penetration Timing
- Biosimilar market share is projected to reach 15%-25% by 2024, then grow to 50%-60% by 2026[3].
Regulatory and Policy Impacts
- The Biosimilar Price Competition and Innovation Act (BPCIA) of 2009 facilitates biosimilar approval and encourages market entry[4].
- Price reductions are driven by payer negotiations and formulary decisions.
- New legislation in various states aims to promote biosimilar substitution, further pressuring Humira pricing.
Key Market Risks
- Slow adoption of biosimilars due to physician and patient preferences.
- Patent litigation delaying biosimilar entry.
- Pricing regulations that could impose price controls or inflation caps.
Conclusions
Humira (NDC 51672-2075) remains a high-value drug with a declining but still significant market share. Price erosion is forecasted at 20%-30% over the next three years due to biosimilar entry. The net price per pen is expected to decline correspondingly. Long-term, the market will stabilize around reduced prices as biosimilar competition consolidates.
Key Takeaways
- The current list price per pen is approximately $2,500.
- Net payer prices are generally $1,200-$1,500.
- Biosimilar competition will cause a 20%-30% price decline over three years.
- Market share for Humira will decrease from approximately 80% to below 50% by 2026.
- Strategic pricing and formulary negotiations will influence ultimate prices and market penetration.
FAQs
Q1: When will biosimilar versions of Humira affect prices significantly?
Biosimilars began entering the U.S. market in 2023, with increasing market share expected over the next three years.
Q2: How does the price of the Humira auto-injector compare to other biologics?
Humira's list price per pen is higher than many biologics, but net prices are comparable after discounts due to its dominant market position.
Q3: What regulatory factors could slow biosimilar price erosion?
Patent litigations and legal challenges can delay biosimilar market entry, prolonging higher prices.
Q4: Will the list price decline reflect real savings for payers?
Not entirely; discounts and negotiations often lead to net prices declining faster than the list prices suggest.
Q5: How will new indications for Humira influence market dynamics?
Expanding indications keep Humira relevant and maintain its market share, despite biosimilar competition.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] EvaluatePharma. (2023). Biosimilar Market Outlook.
[3] Deloitte. (2023). Biologics and Biosimilars Market Trends.
[4] U.S. Congress. (2009). Biosimilar Price Competition and Innovation Act.
